English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia.

MPS-Authors
/persons/resource/persons202089

Matosin,  Natalie
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80333

Gassen,  Nils C.
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80573

Wagner,  Klaus V.
Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80514

Schmidt,  Mathias V.
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

npjschz201622.pdf
(Publisher version), 844KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Matosin, N., Fernandez-Enright, F., Lum, J. S., Engel, M., Andrews, J. L., Gassen, N. C., et al. (2016). Molecular evidence of synaptic pathology in the CA1 region in schizophrenia. NPJ schizophrenia, 2: 16022. doi:10.1038/npjschz.2016.22.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-7A26-E
Abstract
Alterations of postsynaptic density (PSD)95-complex proteins in schizophrenia ostensibly induce deficits in synaptic plasticity, the molecular process underlying cognitive functions. Although some PSD95-complex proteins have been previously examined in the hippocampus in schizophrenia, the status of other equally important molecules is unclear. This is especially true in the cornu ammonis (CA)1 hippocampal subfield, a region that is critically involved in the pathophysiology of the illness. We thus performed a quantitative immunoblot experiment to examine PSD95 and several of its associated proteins in the CA1 region, using post mortem brain samples derived from schizophrenia subjects with age-, sex-, and post mortem interval-matched controls (n=20/group). Our results indicate a substantial reduction in PSD95 protein expression (-61.8%). Further analysis showed additional alterations to the scaffold protein Homer1 (Homer1a: +42.9%, Homer1b/c: -24.6%), with a twofold reduction in the ratio of Homer1b/c:Homer1a isoforms (P=0.011). Metabotropic glutamate receptor 1 (mGluR1) protein levels were significantly reduced (-32.7%), and Preso, a protein that supports interactions between Homer1 or PSD95 with mGluR1, was elevated (+83.3%). Significant reduction in synaptophysin (-27.8%) was also detected, which is a validated marker of synaptic density. These findings support the presence of extensive molecular abnormalities to PSD95 and several of its associated proteins in the CA1 region in schizophrenia, offering a small but significant step toward understanding how proteins in the PSD are altered in the schizophrenia brain, and their relevance to overall hippocampal and cognitive dysfunction in the illness.